查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863428

心臟人工智慧監測和診斷市場（按產品類型、應用、最終用戶、模式和人工智慧技術分類）—2025-2032年全球預測

Cardiac AI Monitoring & Diagnostics Market by Product Type, Application, End User, Modality, AI Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，心臟人工智慧監測和診斷市場將成長至 141.1 億美元，複合年成長率為 29.85%。

主要市場統計數據
基準年 2024 17.4億美元
預計年份：2025年 22.7億美元
預測年份：2032年 141.1億美元
複合年成長率 (%) 29.85%

對心臟人工智慧監測和診斷的發展趨勢、臨床促進因素和關鍵營運挑戰進行了簡明扼要而又全面的概述。

在心臟健康領域，人工智慧正被快速且永續地融入監測和診斷工作流程，從而改變臨床醫生檢測、分層和管理心血管疾病的方式。訊號處理、影像分析和預測演算法的進步使得更早檢測心律不整、更精確地表徵冠狀動脈病變以及持續評估心臟衰竭生理狀態成為可能。這些功能正逐步從專科醫院擴展到門診護理、家庭監測和消費級設備，從而催生新的臨床管道和資料流，而這些都需要嚴格的檢驗、互通性和臨床應用框架。

技術成熟度、感測器發展、監管政策明朗化以及經營模式創新如何共同重塑心臟人工智慧領域的應用管道和競爭格局

心臟人工智慧監測和診斷領域正經歷多重相互關聯的變革，這些變革加速了價值創造，同時也增加了規模化應用的難度。首先，演算法的複雜性已超越概念驗證模型，發展成為能夠整合心電圖分析、影像學和縱向生理數據的臨床相關系統。這種技術成熟度催生了模組化架構。透過將預測分析整合到診斷系統、監測平台和雲端原生臨床決策支援工具中，現在可以實現從急診護理到家庭監測等各種臨床場景的無縫部署。

評估 2025 年關稅變化將如何影響整個心臟人工智慧生態系統（包括硬體和軟體）的製造地、定價策略和採購行為。

2025年關稅調整的累積影響將對供應鏈、採購決策以及心臟人工智慧監測和診斷設備的部署經濟性產生連鎖反應，尤其對於軟硬體整合複雜的產品而言更是如此。影響進口硬體組件、成像系統和穿戴式裝置組裝的關稅可能會推高單位成本，促使製造商重新評估其製造地、重新審視供應商關係並重新考慮定價策略。如果關稅改變了設備的相對成本競爭力，醫院和門診機構的負責人可能會推遲資本投資，或轉向利用現有感測基礎設施的、更具成本效益的純軟體解決方案。

將產品架構、臨床應用、終端用戶環境、模式和人工智慧技術選擇與採用可行性和臨床價值連結起來的綜合細分分析

細分分析揭示了產品架構、臨床應用和最終用戶環境如何交織，從而決定技術採納和價值實現管道。就產品類型而言，診斷系統包括心電圖分析系統和影像分析系統，前者專注於基於訊號的解讀，後者專注於特定模態的影像處理工作流程。監測系統包括植入式、遠端和穿戴式監測器，每種系統在資料收集連續性、侵入性和臨床監測方面各有優劣。預測分析軟體涵蓋患者分層和風險預測，將縱向模型疊加到診斷或監測輸入資料上，以產生可操作的臨床警報並觸發相應的診療路徑。

美洲、歐洲、中東和非洲以及亞太地區在管理體制、採購重點和數位醫療成熟度方面的差異，將影響商業化策略和部署速度。

區域趨勢將以不同的方式影響美洲、歐洲、中東和非洲以及亞太地區的監管預期、採購行為和擴張路徑。在美洲，成熟的支付方環境和部分市場完善的監管管道正在推動人工智慧驅動的診斷和監測解決方案的早期應用，尤其是在那些致力於減少再入院率和管理慢性病的醫療系統中。該市場也傾向於重視臨床證據的產生以及與電子健康記錄系統的整合，以大規模展現其價值。

領先參與企業採取的策略性舉措結合了嵌入式硬體的卓越效能、雲端原生分析以及夥伴關係主導的擴張，旨在加速臨床應用並實現市場差異化。

心臟人工智慧監測和診斷領域的主要企業正在推行差異化策略，將卓越的硬體、演算法創新和生態系統協作相結合，以確保臨床應用。一些現有企業正利用其成熟的影像醫療設備產品組合，將分析功能嵌入現有硬體平台，打造符合醫院採購政策和企業IT需求的整合解決方案。這些公司強調臨床檢驗、與電子病歷的互通性以及長期服務契約，以此作為進入門檻。

為經營團隊提供實用、多方面的指南，幫助他們整合臨床檢驗、模組化產品設計、監管策略和基於結果的商業模式，從而實現規模化發展。

產業領導者應採取多管齊下的策略，將產品開發與臨床通路、監管準備和靈活的商業模式結合。首先，應優先進行臨床檢驗項目，在具有代表性的臨床環境中產生真實世界證據，並重點關注具有臨床意義的終點，例如減少不利事件、提高診斷準確性和降低資源消耗。這些研究應與醫療系統合作夥伴共同設計，以確保其與支付方的決策和報銷申請相關。

採用方法嚴謹的混合方法調查方法框架，結合臨床醫師參與、技術基準化分析和情境分析，以檢驗策略結論。

我們的研究途徑結合了嚴謹的一手研究和二手研究，以確保研究結果的可靠性和相關性。一手研究包括對臨床醫生、醫療系統管理人員、採購人員和技術開發人員進行結構化訪談，以了解實際工作流程、應用障礙和證據需求。此外，我們還組織專家圓桌會議和臨床醫生諮詢小組，以檢驗臨床路徑，並根據實際決策場景對演算法輸出進行壓力測試。

策略重點的整合凸顯了檢驗的效能、互通性和適應性商業化對於確定心臟人工智慧的長期影響和應用的重要性。

總之，心臟人工智慧監測和診斷技術正處於一個策略轉折點，技術能力、不斷變化的監管環境和醫療服務模式的轉變在此交匯，既帶來了巨大的機遇，也帶來了巨大的挑戰。最具影響力的解決方案不僅要展現卓越的演算法效能，還必須融入臨床醫師的工作流程，符合健保報銷原則，並透過模組化設計和適應性商業化策略來抵禦供應鏈和關稅波動的影響。鑑於區域監管和採購方面的差異，本地化的證據生成和基於試點項目的商業化對於建立信任和展現價值至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將深度學習演算法整合到遠端心臟監測平台中，可將心律不整偵測率提高30%以上
  • 一家穿戴式科技製造商與一家人工智慧診斷公司合作，開發用於家庭監測的連續性心房顫動風險預測模型。
  • 透過實施多模態資料融合技術，整合心電圖訊號、血流動力學參數和病患臨床病史，實現個人化心臟人工智慧風險評估。
  • 透過獲得監管部門核准並建立雲端基礎的、人工智慧驅動的心臟影像分析的報銷管道，加速全球市場對該技術的接受度。
  • 引入可解釋的AI框架用於心臟診斷，以增強臨床醫生的信心並滿足不斷變化的FDA透明度要求。
  • 即時人工智慧遠距心臟診斷服務正在興起，用於主動管理農村和資源匱乏地區的心臟衰竭患者。

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 心臟人工智慧監測和診斷市場（按產品類型分類）

  • 診斷系統
    • 心電圖分析系統
    • 影像分析系統
  • 監控系統
    • 植入式監測器
    • 遠端監控
    • 穿戴式監測器
  • 預測分析軟體
    • 患者分層
    • 風險預測

第9章 心臟人工智慧監測和診斷市場（按應用領域分類）

  • 心律不整檢測
    • 心房顫動
    • 室性心搏過速
  • 冠狀動脈疾病診斷
    • 斑塊特徵
    • 狹窄檢測
  • 心臟衰竭管理
    • 體液儲存監測
    • 左心室射血分數（LVEF）評估
  • 高血壓監測
    • 持續血壓監測
    • 偶然血壓篩檢

第10章 按最終用戶分類的心臟人工智慧監測和診斷市場

  • 門診治療中心
    • 診斷實驗室
    • 門診部
  • 診所
  • 居家醫療環境
  • 醫院

第11章 心臟人工智慧監測與診斷市場（按模式分類）

  • CT分析
  • 心電圖監測
    • 靜態心電圖
    • 動態心電圖
  • 超音波心臟檢查分析
    • 多普勒迴聲
    • 2D迴聲
  • 磁振造影分析

第12章：人工智慧技術在心臟人工智慧監測與診斷市場的應用

  • 深度學習
    • 卷積類神經網路
    • 遞迴神經網
  • 整合方法
    • 裝袋
    • 提升
  • 機器學習
    • 邏輯迴歸
    • 隨機森林
    • 支援向量機

第13章：心臟人工智慧監測與診斷市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：心臟人工智慧監測和診斷市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國心臟人工智慧監測與診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Koninklijke Philips NV
    • GE HealthCare Technologies, Inc.
    • Medtronic plc.
    • iRhythm Technologies, Inc.
    • AliveCor, Inc.
    • Apple Inc.
    • Samsung Electronics Co., Ltd.
    • HeartFlow, Inc.
    • Zebra Medical Vision Ltd.
    • Caption Health, Inc.
Product Code: MRR-5C6F41F5AF93

The Cardiac AI Monitoring & Diagnostics Market is projected to grow by USD 14.11 billion at a CAGR of 29.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.74 billion
Estimated Year [2025] USD 2.27 billion
Forecast Year [2032] USD 14.11 billion
CAGR (%) 29.85%

A concise yet comprehensive orientation to the emerging dynamics, clinical drivers, and operational imperatives shaping cardiac AI monitoring and diagnostic innovation

The cardiac healthcare landscape is undergoing a rapid and sustained integration of artificial intelligence into monitoring and diagnostic workflows, reshaping how clinicians detect, stratify, and manage cardiovascular disease. Advances in signal processing, imaging analytics, and predictive algorithms are enabling earlier identification of arrhythmias, more precise characterization of coronary pathology, and continuous assessment of heart failure physiology. These capabilities are progressively migrating from specialized hospital settings into ambulatory care, home monitoring, and consumer-facing devices, creating new clinical pathways and data flows that demand rigorous validation, interoperability, and clinical adoption frameworks.

Adoption is being driven by a convergence of technological maturity, regulatory clarity in key markets, and growing clinical evidence that AI-enabled tools can augment clinician decision-making without replacing essential clinical judgment. At the same time, healthcare systems face pressures to reduce readmissions, optimize diagnostic throughput, and extend specialist expertise into underserved settings. AI-driven cardiac monitoring and diagnostic platforms therefore represent both clinical enablers and operational levers for health systems seeking to deliver higher-value care.

This introduction sets the stage for a deeper analysis of the shifts altering competitive dynamics, how policy variables such as tariffs may influence supply chains, and what segmentation patterns reveal about clinical utility, buying behavior, and deployment environments. Readers should expect a synthesis that connects technical innovation with pragmatic commercialization and regulatory considerations to inform strategic decisions across clinical, product, and market development teams.

How technical maturation, sensor evolution, regulatory clarity, and commercial model innovation are jointly reshaping adoption pathways and competitive positioning in cardiac AI

The landscape of cardiac AI monitoring and diagnostics is being transformed by multiple intertwined shifts that accelerate value creation and complicate the path to scale. First, algorithmic sophistication has moved beyond proof-of-concept models to clinically relevant systems that integrate electrocardiogram analysis, imaging interpretation, and longitudinal physiologic data. This technical maturation is accompanied by modular architectures that allow predictive analytics to be embedded within diagnostic systems, monitoring platforms, and cloud-native clinical decision support tools, thereby enabling more seamless deployment across clinical settings from acute care to home monitoring.

Second, sensor miniaturization, improved battery life, and higher-fidelity signal acquisition have broadened the modalities through which cardiac data are captured. As a result, continuous ECG monitoring and wearable-derived metrics are progressively accepted in clinical pathways for arrhythmia detection and heart failure management. Third, regulatory frameworks are evolving to better accommodate AI-enabled medical devices, with a growing emphasis on post-market performance monitoring and real-world evidence generation. This regulatory evolution lowers some barriers to market entry while raising expectations for sustained clinical validation and transparency around model performance.

Fourth, commercial models are shifting from device-only transactions to outcome-oriented contracting and software-as-a-medical-device (SaMD) subscription models that tie reimbursement and procurement to measurable clinical or operational outcomes. Finally, interoperability and standards work are enabling richer data exchange between ambulatory devices, EHRs, and analytics platforms, accelerating integration into care pathways. Together, these transformative shifts demand that stakeholders design products and commercial strategies that are clinically credible, technically robust, and adaptable to evolving reimbursement and regulatory expectations.

Assessing how 2025 tariff shifts will influence manufacturing footprints, pricing strategies, and procurement behaviors across hardware-software cardiac AI ecosystems

The cumulative impact of tariff changes in 2025 will resonate across supply chains, procurement decisions, and the economics of deploying cardiac AI monitoring and diagnostic equipment, particularly for products with complex hardware-software integrations. Tariffs that affect imported hardware components, imaging systems, or wearable device assemblies increase unit costs and can prompt manufacturers to reassess manufacturing footprints, supplier relationships, and pricing strategies. Where tariffs alter the relative cost competitiveness of devices, buyers in hospitals and ambulatory settings may delay capital purchases or pivot to cost-effective software-only solutions that leverage existing sensing infrastructure.

Tariff-induced price pressures also incentivize firms to accelerate localization of manufacturing or to redesign products to rely more on software and cloud services that are less exposed to duties. However, localization entails near-term capital expenditure and regulatory recertification that can slow product rollouts. For vendors that rely on global supply networks for high-value imaging components or specialized sensors, tariffs can compress margins and push strategic shifts toward partnerships, contract manufacturing in lower-duty regions, or vertical integration to protect supply continuity.

On the payer and provider side, increased device costs may amplify interest in outcome-based procurement models where long-term cost offsets, such as reduced readmissions or avoided procedures, are highlighted to justify higher upfront expenditures. Conversely, smaller clinics and home care providers with tight budgets may postpone adoption of hardware-intensive solutions, increasing demand for remote monitoring services and predictive analytics that can be delivered via existing consumer-grade devices. Ultimately, the 2025 tariff environment will act as an accelerant for strategic choices around manufacturing footprint, product modularity, and commercial structures, and market participants should model tariff scenarios when evaluating capital allocation and partnership strategies.

Integrated segmentation analysis connecting product architectures, clinical applications, end-user environments, modalities, and AI technology choices to adoption potential and clinical value

Segmentation reveals how product architecture, clinical application, and end-user context intersect to determine pathways for technology adoption and value realization. When examining product types, diagnostic systems encompass electrocardiogram analysis systems and imaging analysis systems, with the former focused on signal-based interpretations and the latter on modality-specific image processing workflows. Monitoring systems span implantable monitors, remote monitors, and wearable monitors, each offering different trade-offs between continuity of data capture, invasiveness, and clinical oversight. Predictive analytics software covers patient stratification and risk prediction, layering longitudinal modeling on top of diagnostic or monitoring inputs to create actionable clinical alerts and care pathway triggers.

Applications emphasize specific clinical needs: arrhythmia detection, including atrial fibrillation and ventricular tachycardia subdomains, demands high sensitivity and low false-alarm rates to be clinically useful. Coronary artery disease diagnosis benefits from plaque characterization and stenosis detection capabilities that augment imaging interpretation and support interventional planning. Heart failure management leverages fluid retention monitoring and left ventricular ejection fraction assessment to guide therapy titration, while hypertension monitoring distinguishes between continuous blood pressure monitoring and occasional screening to support preventive care and chronic disease control.

End users range from ambulatory care centers, where diagnostic laboratories and outpatient clinics require rapid throughput and integration with referral workflows, to clinics, home care settings that prioritize ease of use and remote clinician oversight, and hospitals that require enterprise-grade interoperability and regulatory compliance. Modalities further differentiate solutions: CT analysis, ECG monitoring with resting and stress ECG contexts, echocardiogram analysis including Doppler and two-dimensional echo, and MRI analysis; each modality imposes distinct data preprocessing, annotation, and validation requirements. Finally, AI technology choices-deep learning architectures such as convolutional neural networks and recurrent neural networks, ensemble techniques including bagging and boosting, and classical machine learning methods like logistic regression, random forest, and support vector machines-drive both performance profiles and explainability trade-offs. Together, these segmentation lenses indicate that successful solutions will align algorithmic approach to clinical application, optimize modality-specific pipelines, and match delivery models to the practical constraints of target end users.

How divergent regulatory regimes, procurement priorities, and digital health maturities across Americas, Europe Middle East & Africa, and Asia-Pacific determine commercialization strategies and deployment pacing

Regional dynamics shape regulatory expectations, procurement behavior, and pathways to scale in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, a mature payer landscape and established regulatory pathways in some markets support early adoption of AI-enabled diagnostic and monitoring solutions, particularly where health systems are focused on readmission reduction and chronic disease management. This market often favors clinical evidence generation and integration with electronic health record systems to demonstrate value at scale.

The Europe Middle East & Africa region presents heterogeneous regulatory frameworks and reimbursement models that can both accelerate adoption in well-resourced markets and complicate entry elsewhere. Emphasis on data protection, interoperability standards, and national health technology assessment processes requires nuanced market entry strategies that account for localized clinical validation and stakeholder engagement. In the Asia-Pacific region, rapid digital health uptake, large patient volumes, and proactive public-private investment in health infrastructure create opportunities for scalable deployments, though local manufacturing policies and diverse regulatory regimes necessitate adaptive commercialization approaches. Across all regions, partnerships with health systems, strategic pilots to generate region-specific evidence, and tailored pricing models are pivotal to translating product capabilities into clinically adopted solutions.

Strategic approaches by leading players that combine embedded hardware prowess, cloud-native analytics, and partnership-driven expansion to accelerate clinical adoption and market differentiation

Key companies in the cardiac AI monitoring and diagnostics space are pursuing differentiated strategies that blend hardware excellence, algorithmic innovation, and ecosystem partnerships to secure clinical adoption. Some incumbents leverage established imaging and device portfolios to embed analytics into existing hardware platforms, creating integrated solutions that align with hospital procurement preferences and enterprise IT requirements. These firms emphasize clinical validation, interoperability with electronic records, and long-term service contracts as barriers to entry.

Innovative challengers focus on lean software architectures and cloud-native analytics that can be deployed rapidly across ambulatory and home-care settings. Their value propositions center on rapid iteration, consumer-grade user experiences, and scalable data ingestion from wearables and remote monitors. Partnerships between device manufacturers and analytics specialists are common, blending sensing expertise with advanced modeling capabilities to accelerate time to clinical utility. Additionally, a subset of companies is prioritizing explainability and regulatory readiness, investing in transparent model outputs, clinician workflow integration, and post-market performance monitoring to build trust with payers and providers.

Across the competitive set, strategic M&A and co-development agreements are used to fill capability gaps-whether that is advanced imaging analytics, embedded signal processing for implantable monitors, or business development in key regional markets. Firms that succeed will balance rigorous clinical evidence generation with pragmatic commercialization tactics that address procurement cycles, reimbursement realities, and interoperability demands.

Actionable, multi-faceted guidance for executive teams to align clinical validation, modular product design, regulatory strategy, and outcome-based commercial models for scale

Industry leaders should adopt a multi-dimensional strategy that aligns product development with clinical pathways, regulatory readiness, and flexible commercial models. First, prioritize clinical validation programs that generate real-world evidence across representative care settings, focusing on clinically meaningful endpoints such as reduction in adverse events, improved diagnostic yield, and reduced resource utilization. These studies should be designed collaboratively with health system partners to ensure relevance to payer decision-making and reimbursement dossiers.

Second, design modular product architectures that decouple sensor hardware from analytics software, enabling flexible deployment across implantable, remote, and wearable monitoring modalities while reducing exposure to tariff-driven hardware cost volatility. Third, invest in explainability and clinician-facing decision support that integrates seamlessly into existing workflows; embedding transparent model outputs and clear escalation pathways will accelerate clinician trust and adoption. Fourth, pursue regional go-to-market strategies that recognize differences in regulatory requirements and procurement processes, using targeted pilot programs to generate localized evidence and build payer momentum.

Finally, explore outcome-based contracting and subscription models that align vendor incentives with clinical and operational outcomes, and cultivate partnerships with device manufacturers, cloud providers, and health systems to create end-to-end solutions. By synchronizing evidence generation, product modularity, regulatory engagement, and commercial innovation, industry leaders can translate technical advances into sustained clinical and economic value.

A methodologically rigorous mixed-methods research framework combining clinician engagement, technical benchmarking, and scenario analysis to validate strategic conclusions

The research approach combines rigorous primary and secondary methods to ensure robustness and relevancy of findings. Primary research comprises structured interviews with clinicians, health system executives, procurement leads, and technology developers to capture real-world workflows, adoption barriers, and evidence requirements. These interviews are complemented by expert roundtables and clinician advisory panels to validate clinical pathways and to stress-test algorithm outputs against practical decision-making scenarios.

Secondary research synthesizes peer-reviewed literature, regulatory guidance documents, standards publications, and publicly available clinical trial registries to map the evidence landscape. Technical assessment of algorithmic approaches draws on open-source benchmarks and method comparisons to evaluate suitability for specific modalities and clinical applications. Data triangulation is achieved by cross-referencing primary insights with secondary sources and by applying scenario analysis to test the sensitivity of strategic implications to variables such as tariff changes, reimbursement shifts, and technology maturation.

Quality controls include independent peer review of clinical interpretations, reproducibility checks on technical claims, and validation of commercial intelligence through multiple stakeholder confirmations. Where proprietary datasets are used, methodology outlines provenance, preprocessing steps, and limitations to ensure transparent interpretation. This mixed-methods framework yields actionable insights while maintaining methodological rigor appropriate for executive decision-making and product strategy formulation.

Synthesis of strategic priorities showing why validated performance, interoperability, and adaptive commercialization will determine long-term impact and adoption in cardiac AI

In conclusion, cardiac AI monitoring and diagnostics occupy a strategic inflection point where technological capability, regulatory evolution, and changing care delivery models intersect to create substantial opportunity and complexity. The most impactful solutions will not only demonstrate superior algorithmic performance but will also embed into clinician workflows, align with reimbursement rationales, and be resilient to supply chain or tariff disruptions through modular design and adaptive commercialization strategies. Regional nuances in regulation and procurement necessitate localized evidence generation and pilot-based commercialization to build trust and demonstrate value.

Stakeholders should focus on generating clinically meaningful evidence, designing for interoperability and explainability, and engaging payers and providers early to align incentives. Companies that combine validated clinical performance with flexible deployment models and outcome-oriented commercial approaches will be best positioned to capture long-term adoption across hospitals, ambulatory centers, and home care settings. The strategic choices made now about validation, partnerships, and product architecture will determine which organizations transform technological advances into sustained improvements in cardiovascular care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of deep learning algorithms into remote cardiac monitoring platforms to improve arrhythmia detection rates by over thirty percent
  • 5.2. Collaboration between wearable technology manufacturers and AI diagnostics firms to develop continuous atrial fibrillation risk prediction models for home monitoring
  • 5.3. Implementation of multimodal data fusion combining ECG signals, hemodynamic parameters, and patient clinical history for personalized cardiac AI risk profiling
  • 5.4. Regulatory approvals and reimbursement pathways for cloud-based AI-driven cardiac imaging analysis accelerating global market adoption
  • 5.5. Adoption of explainable AI frameworks in cardiac diagnostics to enhance clinician trust and satisfy evolving FDA transparency requirements
  • 5.6. Emergence of real-time AI-enabled telecardiology services for proactive management of heart failure patients in rural and underserved regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac AI Monitoring & Diagnostics Market, by Product Type

  • 8.1. Diagnostic Systems
    • 8.1.1. Electrocardiogram Analysis Systems
    • 8.1.2. Imaging Analysis Systems
  • 8.2. Monitoring Systems
    • 8.2.1. Implantable Monitors
    • 8.2.2. Remote Monitors
    • 8.2.3. Wearable Monitors
  • 8.3. Predictive Analytics Software
    • 8.3.1. Patient Stratification
    • 8.3.2. Risk Prediction

9. Cardiac AI Monitoring & Diagnostics Market, by Application

  • 9.1. Arrhythmia Detection
    • 9.1.1. Atrial Fibrillation
    • 9.1.2. Ventricular Tachycardia
  • 9.2. Coronary Artery Disease Diagnosis
    • 9.2.1. Plaque Characterization
    • 9.2.2. Stenosis Detection
  • 9.3. Heart Failure Management
    • 9.3.1. Fluid Retention Monitoring
    • 9.3.2. LVEF Assessment
  • 9.4. Hypertension Monitoring
    • 9.4.1. Continuous Blood Pressure Monitoring
    • 9.4.2. Occasional Blood Pressure Screening

10. Cardiac AI Monitoring & Diagnostics Market, by End User

  • 10.1. Ambulatory Care Centers
    • 10.1.1. Diagnostic Laboratories
    • 10.1.2. Outpatient Clinics
  • 10.2. Clinics
  • 10.3. Home Care Settings
  • 10.4. Hospitals

11. Cardiac AI Monitoring & Diagnostics Market, by Modality

  • 11.1. CT Analysis
  • 11.2. ECG Monitoring
    • 11.2.1. Resting ECG
    • 11.2.2. Stress ECG
  • 11.3. Echocardiogram Analysis
    • 11.3.1. Doppler Echo
    • 11.3.2. Two D Echo
  • 11.4. MRI Analysis

12. Cardiac AI Monitoring & Diagnostics Market, by AI Technology

  • 12.1. Deep Learning
    • 12.1.1. Convolutional Neural Network
    • 12.1.2. Recurrent Neural Network
  • 12.2. Ensemble Techniques
    • 12.2.1. Bagging
    • 12.2.2. Boosting
  • 12.3. Machine Learning
    • 12.3.1. Logistic Regression
    • 12.3.2. Random Forest
    • 12.3.3. Support Vector Machine

13. Cardiac AI Monitoring & Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiac AI Monitoring & Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiac AI Monitoring & Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Koninklijke Philips N.V.
    • 16.3.2. GE HealthCare Technologies, Inc.
    • 16.3.3. Medtronic plc.
    • 16.3.4. iRhythm Technologies, Inc.
    • 16.3.5. AliveCor, Inc.
    • 16.3.6. Apple Inc.
    • 16.3.7. Samsung Electronics Co., Ltd.
    • 16.3.8. HeartFlow, Inc.
    • 16.3.9. Zebra Medical Vision Ltd.
    • 16.3.10. Caption Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AI TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AI TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CARDIAC AI MONITORING & DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CARDIAC AI MONITORING & DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIAC AI MONITORING & DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AI TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AI TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLO